October 18, 2021

The U.S. FDA has approved Zimhi™ (naloxone HCl) 5mg/0.5mL, a high-dose naloxone injection, to treat opioid overdoses.

  • Zimhi comes in a single-dose, prefilled syringe that can be used by individuals with or without medical It is currently the only FDA-approved 5mg dosage form of naloxone injection.
  • Under the recommended dosing, one single-dose syringe should be injected into the thigh either intramuscularly (into the muscle) or subcutaneously (under the skin) as soon as possible in the event of a known or suspected opioid overdose. Emergency medical assistance should be sought immediately after delivery of the first dose.
  • If the patient does not respond to treatment or relapses into respiratory depression, additional doses can be given every two to three minutes while waiting for emergency medical assistance.
  • Manufacturer Adamis Pharmaceuticals plans to launch Zimhi in the first quarter of 2022.
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More